366 related articles for article (PubMed ID: 20629622)
1. Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target.
Manina G; Pasca MR; Buroni S; De Rossi E; Riccardi G
Curr Med Chem; 2010; 17(27):3099-108. PubMed ID: 20629622
[TBL] [Abstract][Full Text] [Related]
2. Antituberculars which target decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1: state of art.
Buroni S; Pasca MR; de Jesus Lopes Ribeiro AL; Degiacomi G; Molteni E; Riccardi G
Appl Microbiol Biotechnol; 2012 May; 94(4):907-16. PubMed ID: 22526781
[TBL] [Abstract][Full Text] [Related]
3. Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis.
Ribeiro AL; Degiacomi G; Ewann F; Buroni S; Incandela ML; Chiarelli LR; Mori G; Kim J; Contreras-Dominguez M; Park YS; Han SJ; Brodin P; Valentini G; Rizzi M; Riccardi G; Pasca MR
PLoS One; 2011; 6(11):e26675. PubMed ID: 22069462
[TBL] [Abstract][Full Text] [Related]
4. Functional investigation of the antitubercular drug target Decaprenylphosphoryl-β-D-ribofuranose-2-epimerase DprE1/DprE2 complex.
Sammartino JC; Morici M; Stelitano G; Degiacomi G; Riccardi G; Chiarelli LR
Biochem Biophys Res Commun; 2022 Jun; 607():49-53. PubMed ID: 35366543
[TBL] [Abstract][Full Text] [Related]
5. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
6. Current Affairs, Future Perspectives of Tuberculosis and Antitubercular Agents.
Gawad J; Bonde C
Indian J Tuberc; 2018 Jan; 65(1):15-22. PubMed ID: 29332642
[TBL] [Abstract][Full Text] [Related]
7. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis.
Makarov V; Manina G; Mikusova K; Möllmann U; Ryabova O; Saint-Joanis B; Dhar N; Pasca MR; Buroni S; Lucarelli AP; Milano A; De Rossi E; Belanova M; Bobovska A; Dianiskova P; Kordulakova J; Sala C; Fullam E; Schneider P; McKinney JD; Brodin P; Christophe T; Waddell S; Butcher P; Albrethsen J; Rosenkrands I; Brosch R; Nandi V; Bharath S; Gaonkar S; Shandil RK; Balasubramanian V; Balganesh T; Tyagi S; Grosset J; Riccardi G; Cole ST
Science; 2009 May; 324(5928):801-4. PubMed ID: 19299584
[TBL] [Abstract][Full Text] [Related]
8. Decaprenylphosphoryl-β-D-ribose 2'-epimerase, the target of benzothiazinones and dinitrobenzamides, is an essential enzyme in Mycobacterium smegmatis.
Crellin PK; Brammananth R; Coppel RL
PLoS One; 2011 Feb; 6(2):e16869. PubMed ID: 21346818
[TBL] [Abstract][Full Text] [Related]
9. Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis.
Trefzer C; Rengifo-Gonzalez M; Hinner MJ; Schneider P; Makarov V; Cole ST; Johnsson K
J Am Chem Soc; 2010 Oct; 132(39):13663-5. PubMed ID: 20828197
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship mediated molecular insights of DprE1 inhibitors: A Comprehensive Review.
Dash S; Rathi E; Kumar A; Chawla K; Joseph A; Kini SG
J Biomol Struct Dyn; 2024 Aug; 42(12):6472-6522. PubMed ID: 37395797
[TBL] [Abstract][Full Text] [Related]
11. Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones.
Pasca MR; Degiacomi G; Ribeiro AL; Zara F; De Mori P; Heym B; Mirrione M; Brerra R; Pagani L; Pucillo L; Troupioti P; Makarov V; Cole ST; Riccardi G
Antimicrob Agents Chemother; 2010 Apr; 54(4):1616-8. PubMed ID: 20086151
[TBL] [Abstract][Full Text] [Related]
12. Structure, dynamics, and interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies.
Bhutani I; Loharch S; Gupta P; Madathil R; Parkesh R
PLoS One; 2015; 10(3):e0119771. PubMed ID: 25789990
[TBL] [Abstract][Full Text] [Related]
13. DprE1 and Ddn as promising therapeutic targets in the development of novel anti-tuberculosis nitroaromatic drugs.
Paoli-Lombardo R; Primas N; Vanelle P
Eur J Med Chem; 2024 Aug; 274():116559. PubMed ID: 38850856
[TBL] [Abstract][Full Text] [Related]
14. DprE1--from the discovery to the promising tuberculosis drug target.
Mikusová K; Makarov V; Neres J
Curr Pharm Des; 2014; 20(27):4379-403. PubMed ID: 24245764
[TBL] [Abstract][Full Text] [Related]
15. Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.
Balabon O; Pitta E; Rogacki MK; Meiler E; Casanueva R; Guijarro L; Huss S; Lopez-Roman EM; Santos-Villarejo Á; Augustyns K; Ballell L; Aguirre DB; Bates RH; Cunningham F; Cacho M; Van der Veken P
J Med Chem; 2020 May; 63(10):5367-5386. PubMed ID: 32342688
[TBL] [Abstract][Full Text] [Related]
16. High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors.
Christophe T; Jackson M; Jeon HK; Fenistein D; Contreras-Dominguez M; Kim J; Genovesio A; Carralot JP; Ewann F; Kim EH; Lee SY; Kang S; Seo MJ; Park EJ; Skovierová H; Pham H; Riccardi G; Nam JY; Marsollier L; Kempf M; Joly-Guillou ML; Oh T; Shin WK; No Z; Nehrbass U; Brosch R; Cole ST; Brodin P
PLoS Pathog; 2009 Oct; 5(10):e1000645. PubMed ID: 19876393
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Efficacy of the Benzothiazinone BTZ-043 against Tuberculous Mycobacteria inside Granulomas in the Guinea Pig Model.
Eckhardt E; Li Y; Mamerow S; Schinköthe J; Sehl-Ewert J; Dreisbach J; Corleis B; Dorhoi A; Teifke J; Menge C; Kloss F; Bastian M
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0143822. PubMed ID: 36975792
[TBL] [Abstract][Full Text] [Related]
18. Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase.
Landge S; Mullick AB; Nagalapur K; Neres J; Subbulakshmi V; Murugan K; Ghosh A; Sadler C; Fellows MD; Humnabadkar V; Mahadevaswamy J; Vachaspati P; Sharma S; Kaur P; Mallya M; Rudrapatna S; Awasthy D; Sambandamurthy VK; Pojer F; Cole ST; Balganesh TS; Ugarkar BG; Balasubramanian V; Bandodkar BS; Panda M; Ramachandran V
Bioorg Med Chem; 2015 Dec; 23(24):7694-710. PubMed ID: 26643218
[TBL] [Abstract][Full Text] [Related]
19. Synthetic molecules as DprE1 inhibitors: A patent review.
Imran M; A S A; Thabet HK; Abida ; Afroz Bakht M
Expert Opin Ther Pat; 2021 Aug; 31(8):759-772. PubMed ID: 33709862
[TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
